Behavior and knowledge survey to assess the effectiveness of educational materials among healthcare professionals who prescribe AUBAGIO® (teriflunomide) (cross-sectional survey)

Study type

• Study topic:
  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)

  Other
• If ‘other’, further details on the scope of the study:
  Familiarity with Lemtrada educational materials among HCPs
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cross-sectional

Study drug and medical condition

• Medicinal product name:
  AUBAGIO

Population studied

• Short description of the study population:
  HCPs involved in the treatment of MS using Aubagio.; Inclusion criteria; 1. HCP is a neurologist/MS specialist; 2. HCP has already prescribed Aubagio at study entry; 3. HCP supplies informed consent by ticking a box on the survey website.; Exclusion criteria; 1. HCP has not prescribed Aubagio; 2. For Wave 2 only: participation in the questionnaire in Wave 1.
• Age groups:
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Estimated number of subjects:
  0

Study design details

• Main study objective:
  The objective of the study is to assess descriptively knowledge and behavior of HCPs who prescribe Aubagio about the items of the educational materials and thus the effectiveness of these materials to promote the safe and adequate use of Aubagio.
• Outcomes:
  Primary outcomes include the presentation of aggregate HCP responses. Subgroups are defined based on country, specialist role, and type of practice, as well as time since last initiation of Aubagio treatment and number of patients treated with Aubagio seen each month.
• Data analysis plan:
  The study uses descriptive statistics, with a tabulation of the number and frequency of HCP responses.